Total drug treatment and comorbidity in myasthenia gravis: a population‐based cohort study

Autor: Jone Furulund Owe, Nils Erik Gilhus, J. B. Andersen, Anders Engeland
Rok vydání: 2014
Předmět:
Adult
Male
medicine.medical_specialty
Adolescent
Population
Co-morbidity
VDP::Medisinske fag: 700::Helsefag: 800::Epidemiologi medisinsk og odontologisk statistikk: 803
Comorbidity
Drug Prescriptions
Cohort Studies
Young Adult
Pharmacotherapy
Internal medicine
medicine
Humans
VDP::Medisinske fag: 700::Klinisk medisinske fag: 750::Nevrologi: 752
Medical prescription
Child
education
Aged
Aged
80 and over

myasthenia gravis
education.field_of_study
VDP::Midical sciences: 700::Clinical medical sciences: 750::Neurology: 752
Norway
business.industry
Cme Article
Middle Aged
medicine.disease
Myasthenia gravis
Confidence interval
drug therapy
Surgery
Neurology
Pyridostigmine
Cohort
Female
Drug therapy
Neurology (clinical)
VDP::Midical sciences: 700::Health sciences: 800::Epidemiology
medical and dental statistics: 803

business
Pyridostigmine Bromide
medicine.drug
Zdroj: European Journal of Neurology
ISSN: 1468-1331
1351-5101
DOI: 10.1111/ene.12439
Popis: Background and purpose Comorbidity in myasthenia gravis (MG) is important for diagnosis, treatment and prognosis. Disease complexity was assessed by examining total drug treatment, immune therapy and comorbidity in a complete national MG cohort. Methods All recipients of the MG-specific drug pyridostigmine 2004–2010 registered in the compulsory Norwegian Prescription Database who met the inclusion criteria were included. The pyridostigmine group was compared with the general Norwegian population. Results Myasthenia gravis patients received co-medication more often than the controls for nearly all groups of medication, including insulins (95% confidence interval 2.0–3.7), thyroid therapy (1.7–2.5), antidepressants (1.3–1.7), anti-infectives (1.2–1.4), lipid-modifying agents (1.1–1.4) and immunomodulating agents (6.8–8.8). Conclusions Myasthenia gravis patients are more often treated with non-MG prescription drugs than controls, reflecting frequent co-medication and comorbidity.
Databáze: OpenAIRE